Open access peer-reviewed chapter

Peripheral Neuropathy in Connective Tissue Diseases

Written By

Mouna Snoussi, Faten Frikha and Zouhir Bahloul

Submitted: April 23rd, 2018 Reviewed: October 26th, 2018 Published: December 7th, 2018

DOI: 10.5772/intechopen.82271

Chapter metrics overview

1,363 Chapter Downloads

View Full Metrics


Connective tissue diseases are characterized by different organ disorders due to loss of immune system tolerance to autoantigens. Peripheral neuropathy is one of the features of these diseases with variable frequency; it is more prevalent in Sjögren syndrome. Peripheral neuropathy is often seen in the course of the disease. Nonetheless, it may be also a presenting sign or the unique feature of immune system dysfunction. Neuropathies in connective tissue diseases are related mainly to vasculitic disorder. It requires prompt diagnosis and treatment to improve its outcome. Peripheral neuropathy in connective tissue diseases could be multifocal and asymmetric, or confluent and symmetrical. This chapter reviews the clinical, diagnostic and therapeutic features of neuropathies associated with the common diffuse connective tissue diseases.


  • peripheral neuropathy
  • vasculitis
  • connective tissue disease
  • treatment
  • electromyography
  • nerve biopsy

1. Introduction

Connective tissue diseases (CTDs) are defined as a group of acquired diseases resulting from persistent immune-mediated inflammation. They are generally the consequence of autoimmune dysregulation resulting in generation of autoreactive T cells or autoantibodies [1]. Immune disorders can affect any organ of the human body responsible for multisystem involvement. The CTDs classily include systemic lupus erythematosus (SLE), Sjögren syndrome (SS), systemic sclerosis (SSc), dermatomyositis and polymyositis (PM/DM), undifferentiated CTD (UTCD) and overlap syndromes such as mixed CTD (MCTD). Most clinicians do not include systemic necrotizing vasculitis, e.g. polyarteritis nodosa, Churg-Strauss syndrome and Wegener’s granulomatosis in the category of CTD [1]. Peripheral neuropathies (PN) may complicate many different systemic autoimmune diseases. PN in CTD large clinical, histopathological and pathogenic spectrum [2]. We aim in this chapter to precise the epidemiology, the pathogenesis, the diagnosis and the treatment of neuropathies in CTD including systemic lupus erythematosus (SLE), Sjögren syndrome (SS), dermatomyositis and polymyositis (PM/DM), systemic sclerosis (SSc) and mixed CTD (MCTD).


2. Epidemiology of peripheral neuropathy associated with connective tissue diseases and its topographic distribution

PN is one of the clinical features of CTD with variable frequency and prognosis. It is often seen in the course of the disease. However, it may also be a presenting sign or the unique feature of immune system dysfunction [3]. The prevalence of PN is different in the literature series depending on the type of CTD and the means of diagnosis. The incidence of PN in SS is 10–60%, and many of these patients (40–93%) present with neuropathy as the sentinel symptom [4]. PN in SLE patients ranges from 25 to 50% based on electrodiagnostic studies. Curiously, the incidence drops to only 5% based on clinical criteria [5, 6]. Finally, PN is rarely associated with the other CTD, namely, SSc, MCTD, DM and PM [4].

PN refers to the part of a spinal nerve distal to the root and plexus. It is a damage or a disease affecting nerves [7, 8, 9]. Neuropathy affecting one nerve is called “mononeuropathy” and neuropathy affecting multiple nerves in the same areas on both sides of the body is named “symmetrical polyneuropathy”. When separate nerves in disparate areas of the body are affected, the neuropathy is called mononeuritis multiplex, multifocal mononeuropathy or multiple mononeuropathy [8, 10, 11]. Types of neuropathies that are associated with CTD are outlined in Table 1.

Vasculitic neuropathy
 Mononeuropathy multiplex
 Asymmetrical polyneuropathy
 Distal symmetrical polyneuropathy
Distal axonal polyneuropathy
Compression neuropathy
Sensory neuronopathy
Trigeminal sensory neuropathy
Other types of neuropathies associated with connective tissue disease
 Acute demyelinating polyneuropathy
 Chronic demyelinating polyneuropathy

Table 1.

Types of neuropathies associated with CTD (adapted from neuropathies in connective tissue disease/Richard K) [12].


3. Pathogenesis of peripheral neuropathy in connective tissue diseases

The principal components in the pathogenesis of peripheral nerve lesions in diffuse CTD are ischemia due to vasculitis and immune abnormalities. Generally, most of patients have a combination of the ischemic, immunological and metabolic mechanisms of damage to the peripheral nervous system. Nevertheless, one component may be predominant in a different stage of the disease. In systemic scleroderma, the greater role is played by ischemic mechanisms, mainly in the initial states of the disease, while SLE may involve the participation of immunological mechanisms, especially in acute and subacute disease with high level of autoimmune activity [13].

3.1 Vasculitic neuropathy

The immunopathogenesis of vasculitis in CTD is still unclear. The accumulation of immune complexes in the vasa nervorum initiates the leukocytoclastic reaction, which is characterized by segmental fibrinoid necrosis and transmural inflammatory cell infiltration. Vasculitis induces the occlusion of vasa nervorum at the epineurial arteries and produces nerve infarction. Nerve infarcts typically lead to axonal degeneration [14]. Demyelination and conduction block may occur transiently but are usually not a predominant or persistent finding [15]. The clinical and electrophysiological features of neuropathies correlate with the rapidity of onset of ischemia. Acute ischemia induces the development of mononeuropathy, while prolonged circulatory insufficiency is associated with chronic polyneuropathy. The compression-ischemic mechanism leads to the formation of tunnel syndromes [13, 14, 16, 17]. The Peripheral Nerve Society task force has recently proposed a classification that categorizes vasculitic neuropathy into primary systemic vasculitides, secondary systemic vasculitides including CTD and nonsystemic or localized vasculitis on the basis of disease associations [18].

3.2 Autoimmune disorders

Patients with diffuse CTD may have IgG and IgM anticardiolipin antibodies in their serum, which are associated with severe signs of neural lesions, as demonstrated by electromyogram [13]. Moreover, serum levels of anti-nerve growth factor (NGF) antibodies are greater than normal in 32.1% of patients with diffuse CTD. Increased serum levels of anti-NGF are associated with high disease activity and more severe nervous system involvement [13].

3.3 Metabolic disorder

Peripheral nervous system abnormalities in CTD are also explained by metabolic disorder secondary to aggressive therapy, multiorgan pathology and endocrine abnormalities in these patients. Metabolic disorder may induce a reaction of demyelization and axon dystrophy in severe cases [13].


4. Clinical practice guidelines of peripheral neuropathy in CTD

In CTD neuropathic symptoms often start gradually and then get worse. Deep proximal aching pain is the first sign in the affected limb. Burning pain in the cutaneous distribution of the affected nerve is frequent. Weakness and numbness usually appear over several hours to several days after the pain. The delay of the former symptoms is explained by the nerve infarction. On physical examination, most patients have pain and temperature sensory loss in the distribution of the affected nerve. A few patients have impairment of vibration and position sense. Hyporeflexia is also rare except in the ankles. In fact, tendon reflexes other than at the ankle are lost only if the femoral, musculocutaneous, or radial nerves are affected proximally [12, 18, 19]. The quantitative sensory testing (QST) is a tool to analyse the perception in response to external stimuli of controlled intensity. It has been used for the early diagnosis and follow-up of small fibre neuropathies. Although the QST is time-consuming and it is modified also in non-neuropathic pain as in rheumatoid arthritis and inflammatory myalgia, it cannot be taken alone as a conclusive demonstration of PN [20]. The QST is helpful to quantify the effects of treatments on allodynia and hyperalgesia and may reveal a differential efficacy of treatments on different pain components (grade A) [20]. According to EFNS international guidelines, to evaluate hyperalgesia in PN, it is recommended to use simple tools such as a brush and at least one high-intensity weighted pinprick or von Frey filament. The evaluation of pain in response to thermal stimuli is best performed by using the thermotest which is recommended for pathophysiological research or treatment trials. The DN4 may be a useful instrument for the daily diagnostic of PN in CTD [21].


5. Diagnosis and clinical results

In patient with multiorgan involvement and mononeuropathy multiplex, the diagnosis of vasculitic neuropathy is usually easy. However, the diagnosis may be more difficult in less typical presentations of CTD or when peripheral neuropathy is the unique manifestation of the disease. The diagnosis of peripheral neuropathy in CTD particularly in atypical situation is based first on clinical and physical examinations. Electromyography confirms even an underlying axonal neuropathy. The most characteristic electromyographic finding in vasculitic neuropathy described in the previous series is axonal degeneration with multifocal distribution. The typical feature is a low sensory nerve and compound muscle action potential amplitudes in a non-length-dependent distribution with normal or minimally reduced conduction velocities [15, 17, 22, 23]. A partial conduction block is rare, and it is seen transiently and early in stage of nerve ischemia [12]. Laboratory tests may be helpful in establishing the presence of systemic vasculitis or identifying previously undiagnosed connective tissue disease. Evaluation of patients with suspected neuropathy in CTD should include liver and kidney function tests, erythrocyte sedimentation rate, urinalysis as well as a complete blood count. The choice of immunological test including rheumatoid factor, antinuclear antibody, cryoglobulins, antineutrophil cytoplasmic autoantibody and serum complement depends on the clinical presentation of the patient. Nerve biopsy may be helpful in demonstrating vasculitic process. A concomitant muscle specimen is useful to increase diagnostic yield because of the patchy distribution of vasculitic lesions [18].


6. Particularity of PN in each CTD

6.1 Peripheral neuropathy in Sjögren syndrome

Sjögren syndrome is a CTD more prevalent in women at the age of menopause. It is characterized by sicca syndrome and other extra-glandular symptoms. Peripheral nervous involvement in Sjögren syndrome (SS) is reported with variable frequency because of diverse methods for detection of neuropathy and may precede the onset of the disease or be the initial diagnostic clue [24]. The most common feature is symmetrical distal sensory neuropathy, autonomic neuropathy and trigeminal sensory neuropathy. Mononeuritis multiplex, chronic inflammatory demyelinating neuropathy and motor neuropathy are less common [8].

6.1.1 Ganglionopathies

Sensory ganglionopathy is characterized by an impairment of kinesthetic awareness. Patients have the profound handicap of proprioceptive sense affecting larger joints. Electromyogram shows unelicitable sensory nerve action potentials, with preservation of compound motor action potentials [25]. When MRI is performed, it can reveal T2 hyperintensities limited to the gracile and cuneatus tracts of the dorsal spinal cord with sensory neuronopathies [26]. There are two mechanisms evoked in the pathogenesis of gangliopathies in SS. First, the cellular autoimmunity, confirmed by the infiltration of mononuclear and predominantly T cells in the dorsal root ganglia, is associated with cellular degeneration in the absence of vasculitis [25, 27, 28]. Second, recent studies have suggested that the presence of antibodies against the G-bodies, which are a subcellular aggregation of noncoding RNA intermediates and proteins, is associated to neuropathy [29, 30]. Moreover, It was reported that antineuronal antibodies were seen more frequently in Sjögren patients with severe peripheral neuropathy (PN) complications [25].

6.1.2 Small fibre neuropathies

Small fibre neuropathy is the most common PN manifestation of SS. It is a painful, sensory neuropathy affecting the nociceptive A-alpha and unmyelinated C-fibres. Small fibre neuropathy is reported with variable frequency. In the Hopkins Green Sjögren cohort, it was described as the most frequent manifestation [31]. The onset of small fibre neuropathy is usually subacute to chronic, occurring over weeks to months, although cases with hyperacute evolution of hours to days have been reported [27]. The cardinal clinical symptom of isolated small fibre neuropathy is an excruciating burning pain. The physical examination reveals a selective impairment in small-fibre modalities of pinprick and temperature, with relatively preserved vibratory sense and proprioception. The diagnosis of small fibre neuropathy is based on skin biopsy, which assesses the low density of intraepidermal nerve fibres [25, 32].

6.1.3 Sensorimotor polyneuropathies

The majority of studies reported that axonal polyneuropathies as the most frequent type of PN in SS. The onset of sensorimotor polyneuropathy is usually subacute or chronic. The axonal sensory neuropathies are characterized by proprioceptive sensory loss and motor reflexes, and there are diminished sensory nerve action potentials in electromyogram [25]. The sensory symptoms, however, are gradually accompanied by muscle weakness in a distal, symmetrical distribution [32].

6.1.4 Multiple mononeuropathy

It is the transduction of vasculitic neuropathy, and it is very uncommon in SS reported in 0–5% in previous studies. It is usually associated with extra-glandular manifestations [25, 27, 33, 34, 35]. Patients with SS and presenting mononeuritis multiplex should be assessed for cryoglobulinemia polyclonal (types II and III) rather than monoclonal (type I) mainly when there is high-titer rheumatoid factor positivity or when there is disproportionate C4 hypocomplementemia, with normal levels of C3. When nerve biopsy is performed, it may show a lymphocytic or necrotizing vasculitis [32].

6.1.5 Cranial neuropathies

The most common cranial neuropathy in SS is the trigeminal neuropathy, which is usually progressive and can be bilateral and requires symptomatic treatment. Motor dysfunction of cranial nerves is less common, and the facial nerve is the most cranial nerve targeted. The acute onset of cranial neuropathy is due to vasculitic mechanism especially when associated with equally rapid development of multiple mononeuropathies in the extremities [25].

6.1.6 Demyelinating neuropathies

Demyelinating neuropathy is a rare manifestation of SS [32, 33]. Cases of chronic idiopathic demyelinating polyneuropathy have been the subject of case reports in Sjögren patients but have not been substantially described in larger case series. The most common neurophysiologic finding in demyelinating neuropathies was demyelination of the motor nerves [36, 37, 38]. The onset of this neuropathy is subacute and characterized by severe proximal and distal weakness and proprioceptive sensory deficit. Treatment with steroid and sometimes with intravenous immune globulins may be effective [32, 39].

6.1.7 Autonomic neuropathy

Autonomic neuropathy is the rarest type of peripheral nerve involvement in SS because it is usually underdiagnosed. The clinical manifestations of autonomic neuropathy will vary depending on the organs which are affected. Symptoms range from urinary symptoms to severe disabling postural hypotension [27, 32, 38]. In recent studies, autonomic dysfunction is associated with the severity of fatigue in patients with primary SS. However, no association was detected between autonomic dysfunction and exocrine function in these patients [32, 40].

6.2 Peripheral neuropathy in systemic erythematosus lupus

Systemic lupus erythematosus is a multisystem autoimmune disorder with a broad spectrum of clinical presentations as cutaneous, renal and articular manifestations (Figure 1). Affected patients typically have subacute or chronic distal symmetrical polyneuropathies with predominant sensory symptoms. Distal symmetrical axonal degeneration is the major feature of most cases, although other types of peripheral neuropathy have been described [12, 41]. Oomatia reported the subtypes of peripheral neuropathy (PN) attributable to SLE in a group of 82 patients out of 2097 and detailed in Table 2 [42]. Other features such as Guillain-Barré syndrome, plexopathy and autonomic neuropathy are very low in all series [41]. In recent data, small fibre neuropathy is more frequent in SLE, and the decreased intraepidermal nerve fibre density of unmyelinated fibres is a diagnostic test [42]. The mechanisms of peripheral neuropathy in SLE are unclear. Several factors have been reported particularly small-vessel vasculitis and lesions induced by autoimmune antibodies and immune complexes. In series, where nerve biopsy is performed, the anatomopathologic aspect was perivascular mononuclear cell infiltration and variable intimal thickening without necrotizing vasculitis. The presence of necrotizing vasculitis is possible and constitutes a prognostic factor of the disease [12, 41, 43]. Endoneurial mononuclear cell infiltration and increased class II antigen expression were also noticed [12, 43].

Figure 1.

Butterfly rash in systemic lupus erythematosus.

Type of peripheral neuropathy Frequency no. (%)
Axonal neuropathies 46 (56.1)
 Sensory axonal polyneuropathy 19 (23.2)
 Sensorimotor axonal polyneuropathy 21 (25.6)
 Mononeuritis multiplex 6 (7.3)
Small fibre neuropathies 14 (17.1)
Demyelinating polyneuropathies
 Acute inflammatory demyelinating polyneuropathy 1 (1.2)
 Sensory demyelinating polyneuropathy 1 (1.2)
Mixed axonal-demyelinating sensorimotor polyneuropathy 3 (3.6)
Plexopathy 1 (1.2)

Table 2.

Type of peripheral neuropathy in SLE (adapted from peripheral neuropathies in systemic lupus erythematous/Oomatia et al.) [42].

6.3 Peripheral neuropathy in systemic sclerosis

Systemic sclerosis is a rare connective tissue disease with a prevalence of 1 in 10,000 [44]. It is characterized by symmetrical, widespread thickening of the skin (Figure 2) [45]. The prevalence of peripheral neuropathy is unknown with reported ranges in retrospective studies varying from 0.01 to 14% of patients [4647]. Vascular-dependent neuropathy is the principal mechanism inducing a distal symmetric, mainly sensory polyneuropathy as in other connective tissue diseases [13, 46, 47]. Cranial mononeuropathies can also occur, mainly the trigeminal nerve, leading to numbness and dysesthesias in the face. Rarely the seventh and ninth cranial neuropathies are affected [11]. The electrophysiological features are those of sensory axonopathy [11]. Rare cases of mononeuritis multiplex have been mentioned in the course of limited SSc (CREST: calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia) and are due to a necrotizing vasculitis [11].

Figure 2.

Sclerosis of the face in systemic sclerosis.

6.4 Peripheral neuropathy in mixed connective tissue disease

Mixed connective tissue disease is defined as the overlap of SLE, SSc and PM, with a high titer of extractable nuclear antigen and its ribonucleoprotein component [48]. Mild distal axonal polyneuropathy was exceptionally reported in 2 of 20 patients with mixed connective tissue disease, but there has not been a detailed study of the neuropathy or its treatment [48].

6.5 Peripheral neuropathy in dermatomyositis and polymyositis

Nerve involvement in patients with DM is mediated through membrane attack complex (MAC) formation, leading to nerve injury. This entity called “neuromyositis” was first reported in 1890 [49]. Further studies showed a frequency of 7.5% in DM or PM patients with polyneuropathy [50]. Neuropathy due to DM is difficult to diagnose due to necessity of excluding other comorbid etiologic conditions and heterogeneity of muscular manifestations [49]. Nerve biopsy may reveal endothelial vascular injury, and immunohistochemical stains revealed increased expression of perivascular VEGF and demyelinization associated or not with inflammation [51].


7. Treatment of peripheral neuropathy in CTD

7.1 General approach

There are no treatment guidelines specific to each CTD. In general, the management of PN is based on symptomatic treatment of pain as in other causes of neuropathies. Typically, patients with painful polyneuropathies respond to drugs known to be effective for neuropathic pain, including tricyclic antidepressants and a variety of antiepileptic drugs as gabapentin and pregabalin, which is preferred because of its better bioavailability [52]. Concerning the antidepressants, international guidelines provide the same level of recommendation for nonselective tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs). Most clinical trials showed that the efficacy of SNRIs is lower than that of tricyclic antidepressants. However, tricyclic antidepressants have more side effects in elderly and are contraindicated in patients with glaucoma, prostate hypertrophy or some cardiac conduction disturbances. Venlafaxine is a SNRI who has shown efficacy in painful polyneuropathies of different origins [53]. In CTD, PN is mainly due to vasculitic and immune abnormalities. So when vasculitic neuropathy is diagnosed, corticosteroids should be promptly introduced to recover sensory and motor deficits [3]. Most authors recommend starting oral prednisone at high dose of 1 mg/kg per day. In severe cases, intravenous pulses of methylprednisolone of one 1 g for 3–5 days might be appropriate for initial treatment. This treatment should be maintained during the subacute phase, and after 6 to 8 weeks, the treatment should be tapered progressively. Immunosuppressant therapy is associated to corticosteroids in severe forms of vasculitic neuropathy or in systemic vasculitic PN. Cyclophosphamide seems to be the most effective drug for induction of remission and improvement of survival in non-viral systemic vasculitides [18]. Most patients need 3–12 months of cyclophosphamide induction therapy before they can be switched to a maintenance immunosuppressant [54]. Immunosuppressant used as a maintenance therapy is azathioprine, methotrexate and mycophenolate mofetil [55]. Intravenous immunoglobulin is a safe treatment used in serious systemic PN with clinical benefit [18].

7.2 Particularities of treatment in each CTD

Therapeutic strategies of small fibre neuropathy in SS are still unclear. Carbamazepine is generally the first-line agent for trigeminal neuralgia. The use of other antiepileptic agents such as gabapentin should be prescribed with slow titration to minimize its side effects particularly over somnolence and fatigue. The duration of therapeutic trial should be at least 3 months. The secondary amine tricyclic antidepressants such as nortriptyline and desipramine have fewer anticholinergic side effects and a proven efficacy in neuropathic pain, and so they may be slowly prescribed in patients with SS. The use of new immunosuppressant agents mainly monoclonal antibody directed against CD20 antigen on B cells as rituximab and the tumour necrosis factor (TNF)-alpha inhibitors such as adalimumab has been reported to be efficient in the small fibre neuropathies occurring in SS [25]. The management of axonal polyneuropathy is based on a symptomatic treatment; corticosteroids and immunosuppressors are discussed in the case of motor neuropathy with rapid progression [25]. In the case of multiple mononeuropathy, the presence of vasculitis is associated with a good response to immunosuppressive therapy [34]. There is evidence supporting the use of immunoglobulin therapy in Sjögren-associated sensorimotor and nonataxic sensory neuropathy from retrospective and observational cohorts and case reports [56, 57].

In SLE, there are no clear guidelines on the treatment of peripheral neuropathy. Induction treatments with glucocorticoids with or without immunosuppressant agents are indicated in the situation of active vasculitic neuropathy [58]. In the case of necrotizing vasculitis, treatment with plasmapheresis, steroids and immunosuppressant has led to improvement [59, 60]. The definitions of response to treatment are variable between studies. Overall, the rate of global response (complete or partial) is more than 50% [41] (Table 3).

PNS manifestation First-line treatment approach Treatment of refractory cases
Polyneuropathy Neurotrophic agents (tricyclic antidepressants, SNRI (duloxetine, venlafaxine), anticonvulsants (gabapentin, pregabalin)) (glucocorticoids (1 mg/kg/day of prednisone equivalent))
Severe forms: immunosuppressants (azathioprine, mycophenolate mofetil, cyclophosphamide)
High-dose IVIG
Mononeuropathy single/multiple Systemic glucocorticoids (1–2 mg/kg/day of prednisone equivalent or pulses of methylprednisolone 500/1000 mg for 3–5 days with long-term dosage reduction)
Rituximab, IVIG, PEX
Mycophenolate mofetil
Small fibre neuropathy Neurotrophic agents (tricyclic antidepressants,
SNRI (duloxetine, venlafaxine), anticonvulsants
(gabapentin, pregabalin)), topical anaesthetics
Psychological support
Acute inflammatory demyelinating polyradiculoneuropathy (GBS) High-dose IVIG
Cardiorespiratory supporting measures
Glucocorticoids (1 mg/kg/day of prednisone 1000 mg for 3 days)
Equivalent or pulses of methylprednisolone and immunosuppressants – cyclophosphamide
Cranial neuropathy Glucocorticoids (1 mg/kg/day of prednisone equivalent) with long-term dosage reduction
Spontaneous recovery possible for oculomotor involvement
immunosuppressants as maintenance treatment

Table 3.

Treatment options available for peripheral nervous system involvement in patients with SLE (adapted from PNS involvement in SLE/A. Bortoluzzi et al.) [60].

PNS: peripheral nervous system; SNRI: serotonin-norepinephrine reuptake inhibitors; IVIG: intravenous immunoglobulins; PEX: plasma exchange; GBS: Guillain Barré Syndrom.

In SSc, there is not enough data regarding the response of scleroderma-associated neuropathy to immunosuppression [11, 61]. However, this therapy seems to be effective in mononeuritis multiplex and sensorimotor polyneuropathy with inflammatory process [11]. In DM/PM the treatment of PN is based on corticosteroids and immunosuppressant agents depending on the severity of the clinic presentation [51].

PNS, peripheral nervous system; SNRI, serotonin-norepinephrine reuptake inhibitors; IVIG, intravenous immunoglobulins; PEX, plasma exchange; GBS, Guillain-Barré syndrome.


8. Conclusion

8.1 Final considerations

PN is one of the possible neurologic manifestations encountered by physicians in CTD. Coexistence of both conditions is explained by immune-mediated factors particularly a vasculitis of peripheral nerve. Therefore, it is important to take a detailed medical history and examination and then adequate investigations to assess for an underlying systemic autoimmune diseases that may be associated with the neuropathy. Pure sensory and sensorimotor neuropathies are the most common PN features in these disorders. Acute to subacutely evolving multifocal or asymmetric neuropathy suggests a vasculitic cause. This situation constitutes a prognostic factor of the disease and requires prompt treatment with steroids and immunosuppressant agents. The treatment of PN in CTD progresses in three fronts: first, to identify the type of PN through the medical history and physical exam; second, to precise the pathogenic mechanism of neuropathy via clinical presentation, electromyographic data and in unclear situation the nerve biopsy and finally, the efficient control of pain. Corticosteroids remain the mainstay of treatment for vasculitic neuropathy in CTD.

8.2 Futures directions

Although much is known about the PN in CTD, particularly its pathogenesis and its clinical aspects, further experience needs to be gained especially in the treatment with prospective trials to identify indications and precise efficacy for cytotoxic agents, intravenous immunoglobulin, plasma exchange and new biological drugs. In future, we need also further studies to precise clear guidelines to diagnose PN related to CTD such as more specific features in the electromyogram and neuromuscular biopsy. Moreover, in the treatment approach of PN in CTD, we need further researches to identify curative drugs targeting the pathogenesis pathways rather than the symptomatic and the previous conventional therapy.


Conflict of interest

There is no conflict of interest.


  1. 1. Kumar TS, Aggarwal A. Approach to a patient with connective tissue disease. Indian Journal of Pediatrics. 2010;77:1157-1164. DOI: 10.1007/s12098-010-0207
  2. 2. Servioli L, Pérez C, Consani S, et al. Prevalence and characteristics of immuno-mediated neuropathies in a group of patients with autoimmune diseases. Journal of Clinical Neuromuscular Disease. 2007;9:285-290
  3. 3. Matthew NM, Morgenlander JC. Peripheral neuropathy and connective tissue disease. Postgraduate Medicine. 1997;102(5):65-75. DOI: 10.3810/pgm.1997.11.367
  4. 4. Matthew Grantz MD. Unusual peripheral neuropathies. Part II: Intrinsic reactive causes. Seminars in Neurology. 2010;30:396-404
  5. 5. Ilniczky S, Kamondi A, Arányi Z, et al. Simultaneous central and peripheral nervous system involvement in systemic lupus erythematosus. Ideggyógyászati Szemle. 2007;60:398-402
  6. 6. Omdal R, Mellgren SI, Goransson L, et al. Small nerve fiber involvement in systemic lupus erythematosus: A controlled study. Arthritis and Rheumatism. 2002;46:1228-1232. DOI: 10.1002/art.10303
  7. 7. Norman L. Peripheral Neuropathy: When the Numbness, Weakness, and Pain Won’t Stop. New York: American Academy of Neurology Press Demos Medical; 2007
  8. 8. Cojocaru IM, Cojocaru M, Silosi I, Vrabie CD. Peripheral nervous system in autoimmune diseases. MAEDICA – A Journal of Clinical Medicine. 2014;9(3):289-294
  9. 9. Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. The New England Journal of Medicine. 2003;348(13):1243-1255. DOI: 10.1056/NEJMcp022282
  10. 10. Rosenbaum R. Neuromuscular complications of connective tissue diseases. Muscle & Nerve. 2001;24:154-169
  11. 11. Poncelet AN, Connolly MK. Peripheral neuropathy in scleroderma. Muscle & Nerve. 2003;28(3):330-335. DOI:10.1002/mus.10439
  12. 12. Richard K, Olney MD. Neuropathies associated with connective tissue disease. Seminars in Neurology. 1998;18(1):63-72. DOI: 10.1055/s-2008-1040862
  13. 13. Spirin NN, Bulanova VA, Pizova NV, Shilkina NP. Peripheral nervous system lesion syndromes in connective tissue diseases. Neuroscience and Behavioral Physiology. 2007;37(1):1-6. DOI: 10.1007/s11055-007-0141-1
  14. 14. Dyck PJ, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy. Mayo Clinic Proceedings. 1972;47:461-475
  15. 15. Ropert A, Metral S. Conduction block in neuropathies with necrotizing vasculitis. Muscle & Nerve. 1990;13:102-105. DOI: 10.1002/mus.880130203
  16. 16. Chalk CH, Conn DL, Dyck PJ. Vasculitic neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral Neuropathy. Vol. 2. Philadelphia: WB Saunders Co; 1992. pp. 1424-1430
  17. 17. Kissel JT, Mendell JR. Vasculitic neuropathy. In: Dyck PJ, ed. Peripheral neuropathy: New concepts and treatments. Neurologic Clinics. 1992;10(3):761-781
  18. 18. Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. Lancet Neurology. 2014;13:67-82
  19. 19. Hellmann DB, Laing TJ, Petri M, Whiting-O'Keefe Q Parry GJ. Mononeuritis multiplex: The yield of evaluations for occult rheumatic diseases. Medicine (Baltimore). 1988;67:145-153
  20. 20. Cruccua G, Sommera C, Anandd P, Attala N, Baronf R, Garcia-Larreaa L, et al. EFNS guidelines on neuropathic pain assessment: Revised 2009. European Journal of Neurology. 2010;17:1010-1018. DOI: 10.1111/j.1468-1331.2010.02969.x
  21. 21. Bouhassiraa D, Attala N, Alchaarb H, Boureauc F, Brochetd B, Bruxellee J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36
  22. 22. Bouche P, Leger JM, Travers MA, Cathala HP, Castaigne P. Peripheral neuropathy in systemic vasculitis: Clinical and electrophysiologic study-of 22 patients. Neurology. 1986;36:1598-1602
  23. 23. Parry GJ, Brown MJ. Selective fiber vulnerability in acute ischemic neuropathy. Annals of Neurology. 1982;11:147-154. DOI: 10.1002/ana.410110207
  24. 24. Perzyńska-Mazan J, Maślińska M, Gasik R. Neurological manifestations of primary Sjögren’s syndrome. Reumatologia. 2018;56(2):99-105
  25. 25. Birnbaum J. Peripheral nervous system manifestations of Sjögren syndrome: Clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies. The Neurologist. 2010;16:287-297. DOI: 10.1097/NRL.0b013e3181ebe59f
  26. 26. Mori K, Koike H, Misu K, et al. Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neuronopathy associated with Sjogren’s syndrome. Journal of Neurology, Neurosurgery, and Psychiatry. 2001;71:488-492
  27. 27. Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren’s syndrome-associated neuropathy. Brain. 2005;128:2518-2534. DOI: 10.1093/brain/awh605
  28. 28. Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjogren’s syndrome. Annals of Neurology. 1990;27:304-315. DOI: 10.1002/ana.410270313
  29. 29. Bhanji RA, Eystathioy T, Chan EK, et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clinical Immunology. 2007;125:247-256. DOI: 10.1016/j.clim.2007.07.016
  30. 30. Malinow K, Yannakakis GD, Glusman SM, et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjogren’s syndrome. Annals of Neurology. 1986;20:535-537. DOI: 10.1002/ana.410200416
  31. 31. Birnbaum J. Peripheral neuropathy is an uncommon cause of neuropathic symptoms in Sjogren’s patients. Arthritis and Rheumatism. 2009;60(suppl 10):506
  32. 32. Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al. Peripheral neuropathies in Sjögren’s syndrome: A critical update on clinical features and pathogenetic mechanisms. Journal of Autoimmunity. 2012;39:27-33. DOI: 10.1016/j.jaut.2012.01.003
  33. 33. Grant IA, Hunder GG, Homburger HA, et al. Peripheral neuropathy associated with sicca complex. Neurology. 1997;48:855-862
  34. 34. Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjogren’s syndrome-related neuropathy. Arthritis and Rheumatism. 2007;57:1520-1529. DOI: 10.1002/art.23102
  35. 35. Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: A study of 82 patients. Medicine (Baltimore). 2004;83:280-291
  36. 36. Novak V, Freimer ML, Kissel JT, et al. Autonomic impairment in painful neuropathy. Neurology. 2001;56:861-868
  37. 37. Rigamonti A, Lauria G, Balgera R, et al. Subacute inflammatory polyradiculopathy polyradiculopathy associated with Sjogren’s syndrome. Muscle & Nerve. 2009;39:855-857. DOI: 10.1002/mus.21274
  38. 38. Pou Serradell A, Vinas Gaya J. 3 cases of rare peripheral neuropathies associated with primary Gougerot-Sjogren syndrome. Revue Neurologique (Paris). 1993;149:481-484
  39. 39. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nature Reviews. Neurology. 2011. DOI: 10.1038/nrneurol.2011.121
  40. 40. Mandl T, Hammar O, Theander E, Wollmer P, Ohlsson B. Autonomic nervous dysfunction development in patients with primary Sjogren’s syndrome: A follow-up study. Rheumatology (Oxford, England). 2010;49:1101e6. DOI: 10.1093/rheumatology/keq042
  41. 41. Toledano P, Orueta R, Rodríguez-Pintó I, Valls-Solé J, Cervera R, Espinosa G. Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single Centre. Autoimmunity Reviews. 2017 Jul;16(7):750-755. DOI: 10.1016/j.autrev.2017.05.011
  42. 42. Oomatia A, Fang H, Petri M, Birnbaum J. Peripheral neuropathies in systemic lupus erythematosus. Arthritis & Rheumatology. April 2014;66(4):1000-1009. DOI: 10.1002/art.38302
  43. 43. McCombe PA, McLeod JG, Pollard JD, Guo Y-P, Ingall TJ. Peripheral sensorimotor and autonomic neuropathy associated with systemic lupus erythematosus. Brain. 1987;110:S33-S549
  44. 44. LeRoy EC, Silver RM. Systemic sclerosis and related syndromes: Epidemiology, pathology, and pathogenesis. In: Schumacher HR, Klippel JH, Koopman WJ, editors. Primer on the Rheumatic Diseases. 10th ed. Vol. l993. Atlanta: Arthritis Foundation. pp. 118-l20
  45. 45. Medsger TA, Steen V. Systemic sclerosis and related syndromes: Clinical features and treatment. In: Schumacher HR, Klippel JH, Koopman WJ, editors. Primer on the Rheumatic Diseases. 10th ed. Atlanta: Arthritis Foundation; 1993. pp. 120-127
  46. 46. Tagliafico A, Panico N, Resmini E, Derchi LE, Ghio M, Martinoli C. The role of ultrasound imaging in the evaluation of peripheral nerve in systemic sclerosis (scleroderma). European Journal of Radiology. 2011;77(3):377-382. DOI: 10.1016/j.ejrad.2009.08.010
  47. 47. Frech TM, Smith G, Reily M, Chamberlain J, Murtaugh MA, Penrod J, et al. Peripheral neuropathy: A complication of systemic sclerosis. Clinical Rheumatology. 2013;32:885-888. DOI: 10.1007/s10067-013-2206-6
  48. 48. Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed tissue disease. The American Journal of Medicine. 1978;65:955-962
  49. 49. Nguyen TP, Bangert C, Biliciler S, Athar P, Sheikh K. Dermatomyositis-associated sensory neuropathy: A unifying pathogenic hypothesis. Journal of Clinical Neuromuscular Disease. 2014;16:7-11. DOI: 10.1097/CND.0000000000000048
  50. 50. Wang Y, Cui LY, Chen L, et al. Nerve conduction studies in patients with dermatomyositis or polymyositis. Chinese Medical Journal. 2010;123:523-526
  51. 51. Onder H, GökcemYıldız F, Temucin ÇM. Neuromyositis: Clinical and electrophysiological study of 8 cases. Journal of Medicine and Medical Science. 2015;4(7):347-350
  52. 52. Cruccu G, Truini A. A review of neuropathic pain: From guidelines to clinical practice. Pain and Therapy. 2017;6(Suppl 1):S35-S42
  53. 53. Chetty S, Baalbergen E, Bhigjee AI, Kamerman P, Ouma J, Raath R, et al. Clinical practice guidelines for management of neuropathic. South African Medical Journal. 2012;102(5):312-325
  54. 54. Langford CA. Vasculitis. The Journal of Allergy and Clinical Immunology. 2003;111:S602-S612
  55. 55. Langford CA. How can relapses be detected and prevented in primary systemic small-vessel vasculitides? Best Practice & Research. Clinical Rheumatology. 2005;19:307-320. DOI: 10.1016/j.berh.2004.11.003
  56. 56. Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren’s syndrome: A national multicentric retrospective study. Arthritis Care and Research. 2011;63:133944
  57. 57. Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren’s syndrome. Journal of the Neurological Sciences. 2009;279:5761
  58. 58. Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. Journal of Autoimmunity. 2016;74:41-72. DOI: 10.1016/j.jaut.2016.06.013
  59. 59. Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 2011;41:203-211. DOI: 10.1016/j.semarthrit.2011.04.001
  60. 60. Bortoluzzi A, Silvagni E, Furini F, Piga M, Govoni M. Peripheral nervous system involvement in systemic lupus erythematosus: A review of the evidence. Clinical and Experimental Rheumatology. 2018. [Epub ahead of print]
  61. 61. Amarala TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: A systematic review. Seminars in Arthritis and Rheumatism. 2013;43:335-347. DOI: 10.1016/j.semarthrit.2013.05.002

Written By

Mouna Snoussi, Faten Frikha and Zouhir Bahloul

Submitted: April 23rd, 2018 Reviewed: October 26th, 2018 Published: December 7th, 2018